GRML · XBRL financial data

Greenland Mines financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GRML's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†May 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	0	0*	—	0	0	0*	0	239	271	124*	321	401
General and administrative	259	348*	—	2	2,005	(1,924)*	355	339	231	2,151*	6,212	578
Total operating expenses	124	111*	—	396	2,871	1,852*	1,587	1,893	1,853	1,813*	9,512	5,492
Operating income (loss)	(292)	(325)*	—	(396)	(2,871)	(1,852)*	(1,587)	(1,893)	(1,853)	(1,813)*	(9,512)	(5,492)
Interest income	—	year only	—	—	—	—	—	—	—	—	—	—
Interest expense	20	16*	—	15	45	297*	554	1,760	1,178	(1,178)*	2	5
Other income (expense)	0	0*	—	(1)	(85)	84*	11	13	56	35*	16	(3)
Income tax expense (benefit)	149	112*	—	—	—	—	—	—	—	—	—	—
Net income (loss)	290	(126)	—	(452)	(2,959)	(2,067)*	(2,234)	(4,093)	(2,896)	(1,329)*	(13,857)	(3,685)
Earnings per share, basic USD per share	(0.01)	—	—	(0.03)	(0.18)	—	(0.08)	(0.12)	(0.05)	—	(0.15)	(0.03)
Earnings per share, diluted USD per share	(0.01)	—	—	(0.03)	(0.18)	—	(0.08)	(0.12)	(0.05)	—	(0.15)	(0.03)
Weighted average shares, basic thousands of shares	15,130	—	—	15,679	16,689	—	27,524	33,952	59,417	—	93,729	126,521
Weighted average shares, diluted thousands of shares	15,130	—	—	15,679	16,689	—	27,524	33,952	59,417	—	93,729	126,521

† Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 3x in the period ending 2024-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (GRML's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†May 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	146	173	—	845	51	64	566	8,431	7,300	7,177	10,002	9,300
Total current assets	204	200	—	1,000	155	158	688	8,546	7,774	7,294	10,932	12,207
Property and equipment, net	—	—	—	—	—	—	—	—	—	—	—	318
Total assets	58,016	19,456	—	3,309	2,464	2,457	2,987	10,846	10,073	9,593	59,737	65,013
Accounts payable	—	151	—	34	271	64	67	13	35	45	151	698
Accrued liabilities	328	397	—	250	560	912	481	50	58	32	108	213
Total current liabilities	1,664	2,313	—	899	982	1,248	2,338	63	93	77	554	1,210
Total deposits	—	35	35	—	—	—	—	—	—	—	—	—
Total liabilities	7,243	8,242	—	4,861	1,004	1,272	2,349	195	146	130	8,269	7,109
Accumulated deficit	(6,436)	(7,351)	—	(5,536)	(8,496)	(10,563)	(12,797)	(16,890)	(19,786)	(21,114)	(34,972)	(38,657)
Total stockholders' equity	(6,436)	(7,351)	—	(1,551)	1,461	1,185	639	10,650	9,927	9,463	51,469	57,904
Total liabilities and equity	58,016	19,456	—	3,309	2,464	2,457	2,987	10,846	10,073	9,593	59,737	65,013
Common shares outstanding (cover page) thousands of shares	8,802	1,760	5,165	17,230	21,264	28,511	32,494	61,374	72,537	121,239	121,239	158,851

† Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 3x in the period ending 2024-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (GRML's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23†Dec 31, 2023	Q1 FY24†May 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	290	(126)	—	(452)	(2,959)	(2,067)*	(2,234)	(4,093)	(2,896)	(1,329)*	(13,857)	(3,685)
Stock-based compensation	—	—	—	38	1,953	659*	496	390	640	40*	5,107	111*
Net cash from operating activities	(127)*	(249)*	—	(907)*	(1,073)*	(944)*	(1,554)	(1,968)*	(1,088)*	(1,279)*	(4,971)	(6,854)*
Net cash from investing activities	(120)*	39,065*	—	(0)*	0*	0*	—	—	—	—	(365)	(429)*
Proceeds from issuing common stock	—	year only	—	—	—	—	—	—	(495)*	1,107*	7,750	—
Proceeds from issuing equity	—	0*	—	(59,825)*	—	—	—	—	—	—	—	—
Net cash from financing activities	270*	(38,790)*	—	1,720*	279*	957*	2,056	9,834*	5*	1,107*	8,162	6,624*
Net change in cash	23*	—	—	—	—	—	—	—	—	—	—	—

† Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 3x in the period ending 2024-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Greenland Mines	9,300	not reported	(6,854)*	158.9M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.